Health data: Regionalised access is a priority challenge for building a secure, transparent and innovative national health data repository.

IF 2.2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Therapie Pub Date : 2024-12-20 DOI:10.1016/j.therap.2024.12.008
Daniel Szeftel, Vianney Jouhet, Gilles Duluc, Cécile Charle-Maachi, Thomas Sejourné, Jérôme Fabiano, Hélène Guimiot, Aurore Gaignon, Caroline Germain, Quentin Demanet, Emmanuel Merieux, Thomas Rapp
{"title":"Health data: Regionalised access is a priority challenge for building a secure, transparent and innovative national health data repository.","authors":"Daniel Szeftel, Vianney Jouhet, Gilles Duluc, Cécile Charle-Maachi, Thomas Sejourné, Jérôme Fabiano, Hélène Guimiot, Aurore Gaignon, Caroline Germain, Quentin Demanet, Emmanuel Merieux, Thomas Rapp","doi":"10.1016/j.therap.2024.12.008","DOIUrl":null,"url":null,"abstract":"<p><p>France has been engaged in a legal and organisational transition for many years. It has had to adapt its national framework to the legal requirements of personal data protection, European ambitions and international competition. From the Data Protection Act of 1978 to the Healthcare System Transformation Act of 2019, reforms have strengthened requirements in terms of personal data protection, while opening the way to innovative uses. Recent European regulations, such as the AI Act (2024) and the European Health Data Area (2024), aim to reinforce this dynamic, ensuring a secure, transparent and competitive framework for the sharing and use of health data. How can we ensure that the re-use of healthcare data is truly effective, while respecting the fundamental rights of citizens? How can we reconcile national and European ambitions with the technical and organisational realities of the healthcare system, in clinical and research teams, and as close as possible to patients and users in our territories? These questions are essential, because access to and use of health data are seen as major levers for improving the quality of care, supporting innovation and boosting the competitiveness of the French healthcare system. The impact study on the 2019 reform stresses that the transformation of the healthcare system will have to be based on taking better account of the needs of patients and professionals by encouraging local initiatives. In this context, France faces a priority to establish greater coordination between the national and local levels, while preserving the trust of users. This precious trust is essential if we are to make the transition to achieving national and European objectives for the scientific and economic use of data.</p>","PeriodicalId":23147,"journal":{"name":"Therapie","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.therap.2024.12.008","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

France has been engaged in a legal and organisational transition for many years. It has had to adapt its national framework to the legal requirements of personal data protection, European ambitions and international competition. From the Data Protection Act of 1978 to the Healthcare System Transformation Act of 2019, reforms have strengthened requirements in terms of personal data protection, while opening the way to innovative uses. Recent European regulations, such as the AI Act (2024) and the European Health Data Area (2024), aim to reinforce this dynamic, ensuring a secure, transparent and competitive framework for the sharing and use of health data. How can we ensure that the re-use of healthcare data is truly effective, while respecting the fundamental rights of citizens? How can we reconcile national and European ambitions with the technical and organisational realities of the healthcare system, in clinical and research teams, and as close as possible to patients and users in our territories? These questions are essential, because access to and use of health data are seen as major levers for improving the quality of care, supporting innovation and boosting the competitiveness of the French healthcare system. The impact study on the 2019 reform stresses that the transformation of the healthcare system will have to be based on taking better account of the needs of patients and professionals by encouraging local initiatives. In this context, France faces a priority to establish greater coordination between the national and local levels, while preserving the trust of users. This precious trust is essential if we are to make the transition to achieving national and European objectives for the scientific and economic use of data.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
卫生数据:区域获取是建立安全、透明和创新的国家卫生数据存储库的一项优先挑战。
多年来,法国一直在进行法律和组织上的过渡。它不得不调整其国家框架,以适应个人数据保护的法律要求、欧洲的雄心和国际竞争。从1978年的《数据保护法》到2019年的《医疗体系转型法案》,改革加强了对个人数据保护的要求,同时为创新使用开辟了道路。最近的欧洲法规,如《人工智能法》(2024年)和《欧洲卫生数据区》(2024年),旨在加强这一动态,确保共享和使用卫生数据的安全、透明和有竞争力的框架。我们如何确保医疗数据的再利用真正有效,同时尊重公民的基本权利?我们如何使国家和欧洲的雄心与医疗保健系统、临床和研究团队的技术和组织现实,以及尽可能接近我们领土上的患者和用户协调起来?这些问题至关重要,因为卫生数据的获取和使用被视为提高医疗质量、支持创新和提高法国卫生保健系统竞争力的主要杠杆。对2019年改革的影响研究强调,医疗体系的转型必须建立在鼓励地方举措、更好地考虑患者和专业人员需求的基础上。在这方面,法国面临的一个优先事项是在国家和地方各级之间建立更大的协调,同时保持用户的信任。如果我们要过渡到实现国家和欧洲在科学和经济使用数据方面的目标,这种宝贵的信任是必不可少的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Therapie
Therapie 医学-药学
CiteScore
3.50
自引率
7.70%
发文量
132
审稿时长
57 days
期刊介绍: Thérapie is a peer-reviewed journal devoted to Clinical Pharmacology, Therapeutics, Pharmacokinetics, Pharmacovigilance, Addictovigilance, Social Pharmacology, Pharmacoepidemiology, Pharmacoeconomics and Evidence-Based-Medicine. Thérapie publishes in French or in English original articles, general reviews, letters to the editor reporting original findings, correspondence relating to articles or letters published in the Journal, short articles, editorials on up-to-date topics, Pharmacovigilance or Addictovigilance reports that follow the French "guidelines" concerning good practice in pharmacovigilance publications. The journal also publishes thematic issues on topical subject. The journal is indexed in the main international data bases and notably in: Biosis Previews/Biological Abstracts, Embase/Excerpta Medica, Medline/Index Medicus, Science Citation Index.
期刊最新文献
COVID-19 infection and risk of adverse drug reactions: Cohort study. BRAF and MEK inhibitors rechallenge after an adverse drug reaction in patients with cancer: A pharmacovigilance cohort study. [Impact of dronabinol shortage on a population of chronic pain patients: A retrospective observational study]. Lactic acidosis with metformin accumulation in the intensive care units of the Nord Pas de Calais region: A known serious adverse event that can be better prevented. How to facilitate the wider use of pharmacogenetic tests?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1